By challenging how we develop treatments for serious diseases today, Kadmon is developing the cures of tomorrow.

News

February 27, 2012

Kadmon Announces First Patient Dosed in Phase I Study of Selective ROCK2 Inhibitor KD025

January 10, 2012

Kadmon and Chiromics Announce Licensing Agreement for Ground-breaking Chemical Compounds Library

See more news »

Events

January 11, 2012

J.P. Morgan Healthcare Conference

See more events »

California Declaration of Compliance